Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
07:00am, Wednesday, 20'th Aug 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields
NovoCure's Wearable Oncology Edge And Compelling Valuation
12:47am, Wednesday, 30'th Jul 2025
NVCR focuses on Tumor Treating Fields wearables for GBM, mesothelioma, and NSCLC. These are its main recurring revenue verticals. So far, its wearables have shown favorable safety profiles, and su
Why NovoCure Stock Is Cratering Today
02:29pm, Tuesday, 29'th Jul 2025
Shares of Novo Nordisk (NVO -21.28%) are plunging on Tuesday, down 21% as of 2:10 p.m. ET. The drop comes as the S&P 500 (^GSPC) and the Nasdaq Composite (^IXIC) both lost 0.3%.
NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript
04:49pm, Friday, 25'th Jul 2025
NovoCure Limited (NASDAQ:NVCR ) Q2 2025 Earnings Conference Call July 25, 2025 8:00 AM ET Company Participants Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leona
NovoCure Q2 Revenue Jumps 6 Percent
06:37pm, Thursday, 24'th Jul 2025
NovoCure (NVCR -23.93%), the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an
NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say
02:30pm, Thursday, 24'th Jul 2025
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Novocure: Steady Ahead of Key Milestones
09:21am, Thursday, 24'th Jul 2025
Here's our initial take on Novocure's (NVCR -9.99%) fiscal 2025 second-quarter financial report.
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
09:06am, Thursday, 24'th Jul 2025
NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.31 per share a year ago.
Novocure Reports Second Quarter 2025 Financial Results
07:00am, Thursday, 24'th Jul 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend su
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFi
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
10:36am, Monday, 30'th Jun 2025
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Novocure to Report Second Quarter 2025 Financial Results
07:00am, Monday, 30'th Jun 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will
What Makes NovoCure (NVCR) a New Buy Stock
01:00pm, Wednesday, 18'th Jun 2025
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
01:30pm, Friday, 06'th Jun 2025
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
02:05pm, Monday, 02'nd Jun 2025
Zai Lab Limited ZLAB and NovoCure Limited NVCR revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.
